The GREENFUND - we're buying the dip, big time, and here's why., page-134

Some of these posts are ridiculous.

Error bars, data swaps, placebo effects, conspiracy theories.

You've all got to realize, there is no way management are sitting there thinking "oh, let's just wipe $150M MC off the company and sit here as if nothing has happened". That can not be the case. Their phone would be running hotter than the core reactor of Chernobyl.

The only fault I can see in the results is the high vehicle, and potentially the 5% BD readout data line.

Nevertheless, we don't know until we know the causation of such a ridiculous issue. So why so much chatter? No one clearly has an answer. The company will investigate it, and if it's worth updating the market I am sure they will. If not, I am sure they will bury it to save face and the MC. They will need to raise for Ph3 and they can't do it here - I suspect early next year after Ph2 AD results and closer to the FDA meeting.

Those who are entering now, I truly envy you. You are sitting on a company that has a somewhat successful acne drug (Ph2), developing an anti-bacterial line, Ph2 AD results not far out, a rosacea phase 1b trial commencing Q4, and $37M cash in hand.....

If you truly think this is worth $100M irrespective of recent results, then I will be damned.

No one is happy with the way management has dealt with this, no one. Most are holding paper losses (or confirmed losses).

Let's try and look forward rather than dwelling on the could have been.

Biotech stocks slingshot up and down. Let's see what new surprises this week brings.... hopefully not more $150M MC selloffs (lol).